MD Anderson Research Highlights for December 13, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson include a novel blood-based test to predict lung cancer relapses...
ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
ABSTRACT: LBA-2
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS)...
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged...
MD Anderson Research Highlights: ASH 2023 Special Edition
ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983
SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features...
